Skip to main content
Erschienen in:

01.08.2008 | Leitthema

Hochdosistherapie und molekulare Therapie beim kleinzelligen Lungenkarzinom

verfasst von: Dr. B. Fischer, W. Eberhardt, R. Buhl, M. Thomas

Erschienen in: Die Onkologie | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Um die Behandlungsergebnisse beim kleinzelligen Lungenkarzinom (SCLC) zu verbessern, kann der Entwicklung einer Therapieresistenz möglicherweise durch eine Dosisintensivierung entgegengewirkt werden. Ab etwa einer Verdopplung der konventionellen Dosierung ist die Gabe hämatopoetischer Stammzellen erforderlich. Tatsächlich steht der Nachweis einer Prognoseverbesserung durch eine Hochdosistherapie mit Knochenmarkstransplantation und/oder peripherer Blutstammzelltransfusion aus, und eine Reihe von Autoren betrachtet diesen Ansatz beim SCLC als gescheitert.
Die Vielzahl neuer zielgerichteter Substanzen, die zur klinischen Prüfung beim SCLC zur Verfügung stehen, hat einen gewissen Optimismus ausgelöst. Wir stellen die bisher abgeschlossenen Phase-II-und -III-Studien beim SCLC vor. Nach einer ganzen Reihe negativer Studien ruhen derzeit die Hoffnungen auf dem monoklonalen Antikörper Bevacizumab und den Multikinaseinhibitoren, beispielsweise Sorafenib und Sunitinib.
Literatur
1.
Zurück zum Zitat Arnold AM, Seymour L, Smylie M et al. (2007) Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25: 4278–4284PubMedCrossRef Arnold AM, Seymour L, Smylie M et al. (2007) Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25: 4278–4284PubMedCrossRef
2.
Zurück zum Zitat Blackhall FH, Shepherd FA (2007) Small cell lung cancer and targeted therapies. Curr Opin Oncol 19: 103–108PubMedCrossRef Blackhall FH, Shepherd FA (2007) Small cell lung cancer and targeted therapies. Curr Opin Oncol 19: 103–108PubMedCrossRef
3.
Zurück zum Zitat Buchholz E, Manegold C, Pilz L et al. (2007) Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J Thorac Oncol 2: 51–58PubMedCrossRef Buchholz E, Manegold C, Pilz L et al. (2007) Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J Thorac Oncol 2: 51–58PubMedCrossRef
4.
Zurück zum Zitat Chute JP, Chen T, Feigal E et al. (1999) Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 17: 1794–1801PubMed Chute JP, Chen T, Feigal E et al. (1999) Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 17: 1794–1801PubMed
5.
Zurück zum Zitat Crivellari G, Monfardini S, Stragliotto S et al. (2007) Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. Oncologist 12: 79–89PubMedCrossRef Crivellari G, Monfardini S, Stragliotto S et al. (2007) Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. Oncologist 12: 79–89PubMedCrossRef
6.
Zurück zum Zitat Davies AM, Lara PN, Mack PC et al. (2007) Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13: 4647s–4651sCrossRef Davies AM, Lara PN, Mack PC et al. (2007) Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13: 4647s–4651sCrossRef
7.
Zurück zum Zitat Dy GK, Miller AA, Mandrekar SJ et al. (2005) A phase II trial of imatinib (STI 571) in patients with c-kit expressing relapsed small cell lung cancer: a CALGB and NCCTG study. Ann Oncol 16: 1811–1816PubMedCrossRef Dy GK, Miller AA, Mandrekar SJ et al. (2005) A phase II trial of imatinib (STI 571) in patients with c-kit expressing relapsed small cell lung cancer: a CALGB and NCCTG study. Ann Oncol 16: 1811–1816PubMedCrossRef
8.
Zurück zum Zitat Elias A, Ibrahim J, Skarin AT et al. (1999) Dose-intensive therapy for limited stage small-cell lung cancer: long-term outcome. J Clin Oncol 17: 1175–1184PubMed Elias A, Ibrahim J, Skarin AT et al. (1999) Dose-intensive therapy for limited stage small-cell lung cancer: long-term outcome. J Clin Oncol 17: 1175–1184PubMed
9.
Zurück zum Zitat Fetscher S, Brugger W, Engelhardt R et al. (1999) Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. Ann Oncol 10: 561–567PubMedCrossRef Fetscher S, Brugger W, Engelhardt R et al. (1999) Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. Ann Oncol 10: 561–567PubMedCrossRef
10.
Zurück zum Zitat Giaccone G, Debruyne C, Felip E et al. (2005) Phase III study of adjuvant vaccination with Bec2/Bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (EORTC 08971-08971B; Silva study). J Clin Oncol 23: 6854–6864PubMedCrossRef Giaccone G, Debruyne C, Felip E et al. (2005) Phase III study of adjuvant vaccination with Bec2/Bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (EORTC 08971-08971B; Silva study). J Clin Oncol 23: 6854–6864PubMedCrossRef
11.
Zurück zum Zitat Humblet Y, Symann M, Bosly A et al. (1987) Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 5: 1864–1873PubMed Humblet Y, Symann M, Bosly A et al. (1987) Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 5: 1864–1873PubMed
12.
Zurück zum Zitat Iwasaki Y, Nagata K, Nakanishi M et al. (2005) Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer. Chest 128: 2268–2273PubMedCrossRef Iwasaki Y, Nagata K, Nakanishi M et al. (2005) Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer. Chest 128: 2268–2273PubMedCrossRef
13.
Zurück zum Zitat Jänne PA, Freidlin B, Saxman S et al. (2002) Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 95: 1528–1538PubMedCrossRef Jänne PA, Freidlin B, Saxman S et al. (2002) Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 95: 1528–1538PubMedCrossRef
14.
Zurück zum Zitat Johnson BE, Fischer T, Fischer B et al. (2003) Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9: 5880–5887PubMed Johnson BE, Fischer T, Fischer B et al. (2003) Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9: 5880–5887PubMed
15.
Zurück zum Zitat Krug LM, Crapanzano JP, Azzoli CG et al. (2005) Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein. Cancer 103: 2128–2131PubMedCrossRef Krug LM, Crapanzano JP, Azzoli CG et al. (2005) Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein. Cancer 103: 2128–2131PubMedCrossRef
16.
Zurück zum Zitat Lara PN, Chansky K, Davies AM et al. (2006) Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 1: 996–1001PubMedCrossRef Lara PN, Chansky K, Davies AM et al. (2006) Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 1: 996–1001PubMedCrossRef
17.
Zurück zum Zitat Lee SM, Woll PJ, James LE et al. (2007) A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer. J Thorac Oncol 2: S306–S307CrossRef Lee SM, Woll PJ, James LE et al. (2007) A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer. J Thorac Oncol 2: S306–S307CrossRef
18.
Zurück zum Zitat Leyvraz S, Pampallona S, Martinelli G et al. (2006) Randomized phase III study of high-dose sequential chemotherapy supported by peripheral blood progenitor cells for the treatment of small cell lung cancer: results of the EBMT random-ICE trial. Proc Am Soc Clin Oncol. J Clin Oncol 24: 18S #7064CrossRef Leyvraz S, Pampallona S, Martinelli G et al. (2006) Randomized phase III study of high-dose sequential chemotherapy supported by peripheral blood progenitor cells for the treatment of small cell lung cancer: results of the EBMT random-ICE trial. Proc Am Soc Clin Oncol. J Clin Oncol 24: 18S #7064CrossRef
19.
Zurück zum Zitat Leyvraz S, Perey L, Rosti G et al. (1999) Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 17: 3531–3539PubMed Leyvraz S, Perey L, Rosti G et al. (1999) Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 17: 3531–3539PubMed
20.
Zurück zum Zitat Lorigan P, Woll PJ, O’Brien MER et al. (2005) Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 97: 666–674PubMedCrossRef Lorigan P, Woll PJ, O’Brien MER et al. (2005) Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 97: 666–674PubMedCrossRef
21.
Zurück zum Zitat Moore AM, Einhorn LH, Estes D et al. (2006) Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 52: 93–97PubMedCrossRef Moore AM, Einhorn LH, Estes D et al. (2006) Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 52: 93–97PubMedCrossRef
22.
Zurück zum Zitat Pandya KJ, Dahlberg S, Hidalgo M et al. (2007) A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2: 1036–1041PubMedCrossRef Pandya KJ, Dahlberg S, Hidalgo M et al. (2007) A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2: 1036–1041PubMedCrossRef
23.
Zurück zum Zitat Pedrazzoli P, Ledermann JA, Lotz JP et al. (2006) High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 17: 1479–1488PubMedCrossRef Pedrazzoli P, Ledermann JA, Lotz JP et al. (2006) High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 17: 1479–1488PubMedCrossRef
24.
Zurück zum Zitat Pujol JL, Breton JL, Gervais R et al. (2007) Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04-IFCT 00–01. J Clin Oncol 25: 3945–3951PubMedCrossRef Pujol JL, Breton JL, Gervais R et al. (2007) Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04-IFCT 00–01. J Clin Oncol 25: 3945–3951PubMedCrossRef
25.
Zurück zum Zitat Rudin CM, Kozloff M, Hoffmann PC et al. (2004) Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22: 1110–1117PubMedCrossRef Rudin CM, Kozloff M, Hoffmann PC et al. (2004) Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22: 1110–1117PubMedCrossRef
26.
Zurück zum Zitat Rudin CM, Salgia R, Wang X et al. (2008) Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 26: 870–876PubMedCrossRef Rudin CM, Salgia R, Wang X et al. (2008) Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 26: 870–876PubMedCrossRef
27.
Zurück zum Zitat Sandler A, Szwaric S, Dowlati A et al. (2007) A phase II study of cisplatin plus etoposide plus bevacizumab for previously untreated extensive stage small cell lung cancer (E3501): a trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol. J Clin Oncol 25: 18S #7564 Sandler A, Szwaric S, Dowlati A et al. (2007) A phase II study of cisplatin plus etoposide plus bevacizumab for previously untreated extensive stage small cell lung cancer (E3501): a trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol. J Clin Oncol 25: 18S #7564
28.
Zurück zum Zitat Shepherd FA, Giaccone G, Seymour L et al. (2002) Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organisation for Research and Treatment of Cancer. J Clin Oncol 20: 4434–4439PubMedCrossRef Shepherd FA, Giaccone G, Seymour L et al. (2002) Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organisation for Research and Treatment of Cancer. J Clin Oncol 20: 4434–4439PubMedCrossRef
29.
Zurück zum Zitat Spigel DR, Hainsworth JD, Simons L et al. (2007) Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol 2: 854–861PubMedCrossRef Spigel DR, Hainsworth JD, Simons L et al. (2007) Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol 2: 854–861PubMedCrossRef
30.
Zurück zum Zitat Wolf M (2001) Dose intensive chemotherapy in small cell lung cancer. Lung Cancer (Suppl 1) 33: S125–S135 Wolf M (2001) Dose intensive chemotherapy in small cell lung cancer. Lung Cancer (Suppl 1) 33: S125–S135
31.
Zurück zum Zitat Zakowski MF, Ladanyi M, Kris MG et al. (2006) EGFR mutations in small-cell lung cancers in patients who have never smoked. N Eng J Med 355: 213–215CrossRef Zakowski MF, Ladanyi M, Kris MG et al. (2006) EGFR mutations in small-cell lung cancers in patients who have never smoked. N Eng J Med 355: 213–215CrossRef
32.
Zurück zum Zitat Zangemeister-Wittke U, Schenker T, Luedke GH et al. (1998) Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78: 1035–1042PubMed Zangemeister-Wittke U, Schenker T, Luedke GH et al. (1998) Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78: 1035–1042PubMed
Metadaten
Titel
Hochdosistherapie und molekulare Therapie beim kleinzelligen Lungenkarzinom
verfasst von
Dr. B. Fischer
W. Eberhardt
R. Buhl
M. Thomas
Publikationsdatum
01.08.2008
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 8/2008
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-008-1430-1

Weitere Artikel der Ausgabe 8/2008

Die Onkologie 8/2008 Zur Ausgabe

Einführung zum Thema

Kleinzelliges Lungenkarzinom

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.